Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 18/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 18/20 | 0.65 |
| ▸ | PRKDC | P78527 | 18/20 | 0.65 |
| ▸ | ABL1 | P00519 | 16/20 | 0.65 |
| ▸ | EGFR | P00533 | 16/20 | 0.65 |
| ▸ | HCK | P08631 | 16/20 | 0.65 |
| ▸ | SRC | P12931 | 16/20 | 0.65 |
| ▸ | MTOR | P42345 | 16/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 16/20 | 0.65 |
| ▸ | KDR | P35968 | 15/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.64 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.57 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.57 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320603 | 1.00 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL130595 | 0.88 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL13201532 | 0.88 | PIK3CD (0.70) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL130418 | 0.87 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL23997199 | 0.85 | SRC (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL218160 | 0.85 | SRC (0.75) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL130466 | 0.85 | PIK3CD (0.76) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL21436859 | 0.84 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL23917212 | 0.84 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL30320627 | 0.84 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| EP-4161933-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021252488-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252488-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021226547-A2 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| EP-3774797-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | Merck Patent GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| CN-112236429-A | Heteroaryl compounds as type II IRAK inhibitors and uses thereof | 默克专利有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019192962-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019192962-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 145/4885PIK3CA 142/4885PIK3CB 119/4885 |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | PIK3CD 1435/4885PIK3CA 908/4885PIK3CB 1570/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | PIK3CD 3373/4885PIK3CA 3263/4885PIK3CB 3345/4885 |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | IRAK2, IRAK3, IRAK1 | PIK3CD 240/4885PIK3CA 180/4885PIK3CB 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.